Piper Sandler raised AbbVie's price target to $303, indicating a potential 13.92% upside from its current price of $265.97. This reflects positive expectations for the biopharmaceutical company's future performance. Institutional investors like J. M. Brown & Associates, ABN Amro Investment Solutions, and Abundance Wealth Counselors have significantly increased their stakes in AbbVie. Even major asset managers such as Vanguard Group have expanded their holdings, demonstrating broad market confidence in AbbVie's growth prospects.
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
AbbVie announced 34 recipients of its 2026 Immunology Scholarship, supporting students with chronic inflammatory diseases like psoriasis and Crohn's. The scholarship, now renewable for up to four years and worth up to $20,000 annually, helps ease fin...
RoseNose Investing Group's Income Portfolio, yielding 5.6%, reached an all-time high value for the third time in July and is up 12.11% year-to-date. The portfolio includes 15 stocks flagged as overvalued due to their proximity to 52-week highs and lo...
